Physician profile

Peter Torrisi

Pulmonary Disease · Richmond, VA

NPI 1548286370

$1,645.29

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $241.62 2019-2020
Glaxosmithkline, LLC. $233.83 2019-2020
Astrazeneca Pharmaceuticals LP $217.67 2019-2020
Genentech USA, INC. $200.24 2019
Grifols USA, LLC $174.35 2019-2020
Merck Sharp & Dohme LLC $87.65 2019
Sunovion Pharmaceuticals INC. $82.23 2019
Regeneron Healthcare Solutions, INC. $49.21 2019-2020
Actelion Pharmaceuticals US, INC. $48.43 2019
Phadia US INC. $47.54 2019
Gilead Sciences, INC. $44.42 2019
Electromed, INC. $37.99 2019
Insmed, INC. $37.95 2019-2020
Bayer Healthcare Pharmaceuticals INC. $24.79 2019
Genzyme Corporation $22.74 2019
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Mallinckrodt Hospital Products INC. $21.33 2020
Philips North America LLC $17.62 2019
Novartis Pharmaceuticals Corporation $15.90 2019
Mallinckrodt Enterprises LLC $15.42 2019
Circassia INC. $12.75 2019
Allergan, INC. $11.61 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Peter Torrisi

$1,645.29

in general payments reported 2019-2025

Years
2019-2020
Top company
Boehringer Ingelheim Pharmaceuticals, INC.

https://glasscript.com/doctor/206676/peter-torrisi

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.